AK104 plus radiation for colorectal cancer spread to liver
Part of Cancer clinical trials.
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Colorectal cancer confirmed by biopsy with spread to the liver
- At least one measurable tumor spot in the liver suitable for radiation treatment
- No prior cancer treatment, or recurrence after surgery with no treatment in the past 6 months
- Good overall health (able to do daily activities with minimal limitations)
- Normal blood cell counts, liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This trial tests a combination of two study drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments. It aims to see if the combination can help shrink tumors.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hear when a new Colorectal Cancer Liver Metastases (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.